{"id":"NCT04627285","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment","officialTitle":"A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-28","primaryCompletion":"2025-02-12","completion":"2025-02-12","firstPosted":"2020-11-13","resultsPosted":"2025-08-28","lastUpdate":"2025-08-28"},"enrollment":48,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":[]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"From visit 1 (Week 0) to the end of study visit (up to Week 214.42)","effectByArm":[{"arm":"Lacosamide: >=2 to <4 Years","deltaMin":42.1,"sd":null},{"arm":"Lacosamide: >=4 to <6 Years","deltaMin":37.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":15,"countries":["Georgia","Hungary","Moldova","Romania","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":19},"commonTop":["Upper respiratory tract infection"]}}